Roche ’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types
If approved, Tecentriq subcutaneous (SC) would be the first injectable PD-(L)1 cancer immunotherapy in the EU, cutting treatment time by approx. 80%1 The CHMP recommended Tecentriq SC for all indications of intravenous (IV) Tecentriq, including certain types of lung, liver, bladder and breast cancer2A majority of healthcare professionals surveyed in the IMscin001 study found that the SC formulation is easy to administer and could save time compared with IV1Basel, 14 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (C...
Source: Roche Media News - November 14, 2023 Category: Pharmaceuticals Source Type: news
Mayo Clinic expert on the importance of lung cancer screening
Screening for lung cancer can save lives, and there's an urgent need for more screening of people of color. That's one of the takeaways from the newly released "State of Lung Cancer" report from the American Lung Association. "Lung cancer is the largest (cancer) killer of adult men and women worldwide. Many of the reasons for that is it's so late in its stage, often, when it's diagnosed," says Dr. Janani Reisenauer, a thoracic surgeon… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - November 14, 2023 Category: Databases & Libraries Source Type: news
Why I'm Sticking With the USPSTF on Lung Cancer Screening Why I'm Sticking With the USPSTF on Lung Cancer Screening
ACS recommends continuing lung cancer screening to age 80, regardless of how long ago patients quit smoking. Dr Kenny Lin explains why he ' s following the USPSTF ' s recommendations for now.Medscape Family Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 13, 2023 Category: Consumer Health News Tags: Family Medicine/Primary Care Commentary Source Type: news
Road to RSNA 2023: CT
Photon-counting CT (PCCT) has dominated discussion for the last number of RSNA meetings, and this year will be no exception. Expect to hear PCCT research findings about how the technology can increase image quality and lower radiation dose in pulmonary angiography for the diagnosis of pulmonary embolism; how it appears to boost the contrast-to-noise ratio of vascular structures on chest CT; and what it has to offer in the musculoskeletal arena.
Meeting attendees will also get the scoop on the role CT radiomics can play in clinical care, particularly helping clinicians determine the best treatment for patients sufferi...
Source: AuntMinnie.com Headlines - November 13, 2023 Category: Radiology Authors: Kate Madden Yee Tags: 2023 2023 CT Preview Source Type: news
CT-based deep learning radiomics may help determine NSCLC treatment
Thursday, November 30 | 11:10 a.m.-11:20 a.m. | R4-SSCH10-2 | Room S405 A CT-based deep-learning radiomics biomarker appears to characterize the level of expression of programmed cell death ligand 1 (PD-L1) in non-small cell lung cancers (NSCLCs), according to study results that will be presented Thursday morning.The findings could help clinicians set treatment for lung cancer patients, since tumors that express 50% or greater levels of PD-L1 tend to respond well to immunotherapy, wrote a team led by Jingshan Gong, MD, of Shenzhen Second People's Hospital in China.The study included 259 patients with pathology-confirmed ...
Source: AuntMinnie.com Headlines - November 13, 2023 Category: Radiology Authors: Kate Madden Yee Tags: 2023 CT Preview Source Type: news
TLS in Tumors May Predict Immunotherapy Benefit in NSCLC TLS in Tumors May Predict Immunotherapy Benefit in NSCLC
New data indicate that tertiary lymphoid structures could predict which patients with advanced non-small cell lung cancer will benefit most from immunotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 10, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
SAN DIEGO, Calif. and ZUG, Switzerland, Nov. 10, 2023 -- (Healthcare Sales & Marketing Network) -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that following a re-examination procedure, the Comp... Biopharmaceuticals, Oncology, Regulatory Mirati Therapeutics, KRAZATI, adagrasib, Non-Small Cell Lung Cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 10, 2023 Category: Pharmaceuticals Source Type: news
Lung cancer pill that HALVES patients' risk of death is hailed 'earth-shattering' by specialists
Osimertinib can slash the risk of the disease returning by more than 70 per cent, and cuts deaths in half. (Source: the Mail online | Health)
Source: the Mail online | Health - November 9, 2023 Category: Consumer Health News Source Type: news
2023 Guidelines Update Eligibility for Lung Cancer Screening
THURSDAY, Nov. 9, 2023 -- In a guideline update issued by the American Cancer Society and published online Nov. 1 in CA: A Cancer Journal for Clinicians, the authors recommend increasing eligibility for lung cancer screening (LCS).Andrew M.D. Wolf,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 9, 2023 Category: Pharmaceuticals Source Type: news
Deep-learning model can spot patients at high risk of COPD
Thursday, November 30 | 8:20 a.m.-8:30 a.m. | R1-SSCH09-3 | Room E352This scientific presentation will present external validation results for a deep-learning model in identifying individuals at high risk of incident chronic obstructive pulmonary disease (COPD) on routine outpatient chest x-rays (CXR).Saman Doroodgar Jorshery, MD, and colleagues will discuss findings with CXR-Lung-Risk, a previously developed convolutional neural network designed to predict lung-related mortality. For the external validation, patients with no history of lung cancer, COPD, or emphysema, and who had a chest radiograph, were identified.After ...
Source: AuntMinnie.com Headlines - November 9, 2023 Category: Radiology Authors: Liz Carey Tags: 2023 Digital X-Ray Preview Source Type: news
Road to RSNA 2023: Women's Imaging Preview
Women’s imaging has a lot going for it at RSNA 2023 in Chicago. A large variety of methods and modalities will be showcased for breast cancer screening, diagnosis, and treatment, as well as other pathologies. Supplemental screening takes center stage at the meeting as researchers highlight the roles of imaging modalities such as MRI, ultrasound, and molecular breast imaging in confirming suspicious findings on screening mammography. Along with that, radiologists are tackling the challenge of screening for dense breasts, an issue that has come under intense focus in recent years.In scientific presentations, researchers wi...
Source: AuntMinnie.com Headlines - November 9, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: 2023 2023 Women's Imaging Preview Source Type: news
Lung cancer still biggest cancer killer, but death rates are improving, report finds
Canada's annual report on cancer statistics says more people with lung cancer are surviving. (Source: CBC | Health)
Source: CBC | Health - November 8, 2023 Category: Consumer Health News Tags: News/Health Source Type: news
CT Screening Greatly Boosts Lung Cancer Survival: Study
WEDNESDAY, Nov. 8, 2023 -- For smokers and former smokers, getting annual CT scans of the chest to catch lung cancers early dramatically improves survival, new research shows.Many people may believe lung cancer to be swiftly fatal. However, the new... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 8, 2023 Category: General Medicine Source Type: news
What You Need To Know About Lung Cancer Screening In America
Screening rates for lung cancer remain low. In America, only 5.8% of those that are eligible to get screened are getting the study that could save their life. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 8, 2023 Category: Pharmaceuticals Authors: Omer Awan, Contributor Tags: Healthcare /healthcare Innovation /innovation standard Source Type: news
1 In 10 At Risk Of Lung Cancer Get Screened. Awareness Could Save Countless Lives
Screening rates for lung cancer remain low. In America, only 5.8% of those that are eligible to get screened are getting the study that could save their life. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 8, 2023 Category: Pharmaceuticals Authors: Omer Awan, Contributor Tags: Healthcare /healthcare Innovation /innovation standard Source Type: news
